Oncology Brothers: Practice-Changing Cancer Discussions
Oncology Brothers
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Episodes
Mentioned books
Nov 26, 2025 • 17min
FDA Approval of Durvalumab with FLOT in Resectable Gastric & GEJ: MATTERHORN by Dr. Yelena Janjigian
In this episode of The Oncology Brothers, we dived into the pivotal study of MATTERHORN, which explored the addition of Durvalumab to perioperative FLOT chemotherapy for patients with resectable gastric and gastroesophageal junction adenocarcinoma.
Join us as we welcome Dr. Yelena Y. Janjigian, a medical oncologist from Memorial Sloan Kettering and the lead author of the MATTERHORN study. Dr. Janjigian shared insights on the study's design, findings, and the implications for clinical practice, including:
• The significance of the study in the context of recent FDA approvals and treatment advancements.
• Key survival data, including a three-year overall survival rate of 68.6% with Durvalumab.
• The feasibility of combining immunotherapy with chemotherapy and impact on surgical outcomes.
• Management of side effects and clinical pearls for practitioners.
We also discussed the potential for extrapolating this data to esophageal adenocarcinoma and the role of PD-L1 status in treatment decisions.
Whether you're a seasoned oncologist or just starting in the field, this episode is packed with valuable information to help you provide the best care for your patients.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, share, and subscribe for more practice-changing updates in oncology!
#MATTERHORN #GastricCancer #Immunotherapy #Durvalumab #OncologyBrothers #GIOncology
Nov 24, 2025 • 24min
Challenging Cases in Breast Cancer with CDK 4/6 Inhibitors – Drs. Sara Tolaney & Adam Brufsky
In this episode of the Oncology Brothers podcast, we took a deeper dive into the evolving landscape of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Joined by esteemed oncologists Dr. Sara Tolaney from Dana-Farber Cancer Institute and Dr. Adam Brufsky from UPMC Hillman Cancer Center, the discussion focused on real-world scenarios involving adjuvant and metastatic settings.
Key topics included:
• The recent updates from the MonarchE and NATALEE trials, highlighting the approval of abemaciclib and ribociclib.
• Strategies for selecting the right adjuvant treatment for high-risk patients, including dosing considerations and side effect management.
• Insights into managing common toxicities associated with CDK4/6 inhibitors, such as diarrhea and QTc prolongation.
• The role of CDK4/6 inhibitors in patients with visceral involvement and the implications of using these therapies in the metastatic setting.
Whether you're a healthcare professional or someone interested in the latest advancements in breast cancer treatment, this episode provided valuable insights and expert opinions on navigating complex treatment decisions.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes and send us your challenging cases for future discussions!
#CDK4/6i #BreastCancer #MonarchE #NATALEE #Abemaciclib #Ribociclib #OncologyBrothers #HRpositive
Nov 20, 2025 • 23min
Challenging Cases in Non-Muscle Invasive Bladder Cancer (NMIBC) – Drs. Shilpa Gupta & Joshua Meeks
In this episode of the Oncology Brothers podcast, we dived deep into the rapidly evolving landscape of non-muscle invasive bladder cancer (NMIBC) treatment. Joined by expert guests Dr. Joshua Meeks, a urologist from Northwestern University, and Dr. Shilpa Gupta, a medical oncologist from Cleveland Clinic, the discussion focused on the integration of immunotherapy into non-muscle invasive bladder cancer.
Key topics included:
The definition and characteristics of high-risk non-muscle invasive bladder cancer.
Recent clinical trials, including the CREST and POTOMAC, exploring the combination of immunotherapy with BCG treatment.
The evolving role of medical oncologists in managing NMIBC and the importance of a multidisciplinary approach.
Patient-centered discussions on treatment options, event-free survival, and managing side effects of immunotherapy.
Join us as we unpack the latest data and real-life scenarios in NMIBC, emphasizing the critical need for collaboration between urologists and medical oncologists to improve patient outcomes.
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology!
#NMIBC #BladderCancer #Immunotherapy #BCG #Urology #OncologyBrothers #GUCancer
Nov 17, 2025 • 20min
FDA Approval of Ziftomenib (KOMET-001) in NPM1 mut Acute Myeloid Leukemia (AML) – Dr. Eunice Wang
In this episode of the Oncology Brothers podcast, we dived into the exciting world of cancer treatment with a focus on the recent FDA approval of Ziftomenib for relapsed refractory NPM1 mutated acute myeloid leukemia (AML).
We were joined by Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center as our guest. Dr. Wang shared insights from the KOMET-001 study, detailing the study design, efficacy, and safety profile of Ziftomenib. With a response rate of nearly 30% and significant overall survival benefits for patients, this new treatment option is a promising step forward in managing heavily pretreated AML.
Key topics covered in this episode included:
The mechanism of action of Ziftomenib as a menin inhibitor
Study findings from KOMET-001 and patient response rates
Management of side effects, including differentiation syndrome and QTc prolongation
Comparison with other menin inhibitors like Revumenib
Future directions for combination therapies and sequencing of treatments
Whether you're a healthcare professional, a patient, or simply interested in the latest advancements in cancer therapy, this episode is packed with valuable information.
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights into FDA approvals, toxicity management, and practice-changing conference highlights.
#Ziftomenib #MeninInhibitor #AML #NPM1 #Leukemia #FDAapproval #OncologyBrothers
Nov 13, 2025 • 16min
Managing Toxicities of ROS1 Inhibitors in Non-Small Cell Lung Cancer (NSCLC) – Dr. Estela Rodriguez
Welcome to the Oncology Brothers podcast! In this episode, we dive into the management of ROS1 fusion positive non-small cell lung cancer (NSCLC) and explore the various tyrosine kinase inhibitors (TKIs) available for this rare subset of patients.
Join us along with special guest Dr. Estelamari Rodriguez, a thoracic medical oncologist from Sylvester Comprehensive Cancer Center, as we discussed:
• The importance of comprehensive next-generation sequencing (NGS) in management of NSCLC.
• A detailed overview of ROS1 TKIs, including crizotinib, repotrectinib, entrectinib, taletrectinib.
• Common side effects associated with these agents, such as fatigue, dizziness, edema, and liver toxicity.
• Clinical pearls for managing adverse events and optimizing patient care.
• The significance of patient education and regular follow-ups in ensuring treatment adherence and safety.
Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into the practical aspects of treating ROS1 fusion positive NSCLC.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to check out our other ToxCheck episodes, conference highlights, and treatment algorithms. Subscribe for more discussions on bridging the gap between academic research and community practice!
#ROS1 #NSCLC #TKIs #Crizotinib #Repotrectinib #Entrectinib #Taletrectinib #TargetedTherapy #OncologyBrothers #LungCancer
Nov 10, 2025 • 22min
Managing Toxicities of Tyrosine Kinase Inhibitors (TKI) in CML - Drs. Onyee Chan & Fadi Haddad
In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML).
Join us as we delve into:
• An overview of the different generations of TKIs, including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib.
• Common class-wide toxicities such as fatigue, hypertension, gastrointestinal symptoms, and cytopenias.
• Unique side effects associated with each TKI and strategies for dose optimization.
• The importance of patient education and monitoring to ensure effective management of side effects.
Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T therapies, and more!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Subscribe to the Oncology Brothers for more discussions on bridging the gap between academic research and community practice in cancer care!
#CML #TKI #ToxCheck #Hematology #OncologyBrothers #PrecisionMedicine
Nov 6, 2025 • 25min
Lung Cancer ESMO 2025 Highlights: MDT-BRIDGE, FLAURA2, SOHO-01, Beamion LUNG-1
Dr. Rami Manochakian, a thoracic oncologist from the Mayo Clinic, shares groundbreaking insights from ESMO 2025 on lung cancer. He highlights the significance of the MDT-BRIDGE trial, which showcases a multidisciplinary approach for non-small cell lung cancer. The conversation dives into the FLAURA2 study, showing survival benefits of osimertinib with chemotherapy. Plus, he introduces promising HER2-targeted therapies like Zongertinib and Sevabertinib, emphasizing the need for upfront NGS testing to personalize treatment strategies.
Nov 3, 2025 • 19min
GI Cancer ESMO 2025 Highlights: DYNAMIC-III, PEGASUS, STELLAR-303, MATTERHORN, FORTITUDE-101
In this episode of the Oncology Brothers podcast, we dived into the key takeaways from ESMO 2025, focusing on gastrointestinal (GI) malignancies. Join us as we welcomed Dr. Rachna Shroff, a GI medical oncologist from the University of Arizona, to discuss the latest studies and their implications for clinical practice.
Episode Highlighted:
• ctDNA in Colorectal Cancer: DYNAMIC-III and PEGASUS studies, examining the evolving role of ctDNA as a prognostic and potential predictive tool in early-stage colon cancer.
• STELLAR-303: Learn about the promising results of immunotherapy in refractory MSI-stable colorectal cancer and the associated toxicities.
• MATTERHORN: Updated data on durvalumab with FLOT in the perioperative setting is changing the standard of care for upper GI malignancies.
• FORTITUDE-101 Study: FGFR2b target in metastatic gastric and GE junction adenocarcinoma.
Tune in for an insightful discussion that highlights the latest advancements in oncology and their potential impact on patient care.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to check out our previous episodes for more insights on conference highlights, recent approvals, and treatment algorithms.
#ESMO2025 #GIOcology #ctDNA #ColorectalCancer #Immunotherapy #OncologyBrothers #PrecisionMedicine
Oct 30, 2025 • 22min
Breast Cancer ESMO 2025 Highlights: MonarchE, NATALEE, VIKTORIA1, evERA, DESTINY, ASCENT, TROPION
In this episode of the Oncology Brothers podcast, we are joined by Dr. Virginia Kaklamani from UT San Antonio to discuss the practice changing/informing findings from ESMO 2025, particularly in the realm of breast cancer.
We dived deep into the most impactful studies, including:
• MonarchE/NATALEE: Discover additional follow-up results from abemaciclib and ribociclib, where abemaciclib now has overall survival benefit in adjuvant HR+ settings.
• Metastatic HR+ Disease: Insights on the latest data surrounding PIK3CA mutations, with results from the VIKTORIA1 trial with Gedatolisib, and evERA study with Giredestrant.
• HER2+ Breast Cancer: A comprehensive look at the DESTINY trials, highlighting the efficacy of Trastuzumab Deruxtecan (TDXd) in both neoadjuvant, adjuvant and palliative settings.
• Triple Negative Breast Cancer: The role of sacituzumab and Dato-DXd in the first-line treatment landscape.
Join us as we unpack these complex studies, discuss clinical implications, and share practical insights for community oncologists.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
#ESMO2025 #BreastCancer #MonarchE #NATALEE #DESTINYtrials #CDK4/6 #ADCs #OncologyBrothers
Oct 27, 2025 • 15min
Current Treatment Landscape of Ovarian Cancer with Dr. Sharyn Lewin
Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Sharyn Lewin, the Director of Gynecology Oncology at Holy Name Medical Center, to explore the evolving treatment landscape of ovarian cancer.
Join us as we discuss:
• The importance of surgical staging and debulking surgery in ovarian cancer treatment.
• The role of neoadjuvant chemotherapy and the significance of germline testing.
• Current systemic treatment paradigms, including the use of PARP inhibitors and Bevacizumab.
• Insights into the management of refractory disease and the latest options available for patients.
• The impact of biomarker testing and the importance of understanding HRD status.
Dr. Lewin shared her expertise on the latest clinical data, treatment strategies, and the implications of testing for patients and their families.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell to stay updated on our upcoming episodes, including our next discussion on endometrial cancer!
#OvarianCancer #PARPinhibitors #GermlineTesting #GynOnc #OncologyBrothers #MaintenanceTherapy #PersonalizedMedicine
